Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study.

Matucci-Cerinic, M, Allanore, Y, Kavanaugh, A et al. (8 more authors) (2018) Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. RMD Open, 4 (2). e000757. ISSN 2056-5933

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © Author(s) (or their employer(s)) 2018. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0
Keywords: GP2015; bioequivalence; biosimilar; etanercept; rheumatoid arthritis
Dates:
  • Published: 11 October 2018
  • Accepted: 4 October 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Clinical Musculoskeletal Medicine (LIRMM) (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 10 Dec 2018 10:43
Last Modified: 10 Dec 2018 10:43
Status: Published
Publisher: BMJ Publishing Group
Identification Number: https://doi.org/10.1136/rmdopen-2018-000757
Related URLs:

Download

Share / Export

Statistics